GSK To Sell $740 Million Worth Of Aspen, Retaining 13% Stake
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline plans to reduce its 19% stake in Aspen Pharmacare by selling off 6% of its shares for $740 million, but said the sale would not affect its four-year-old partnership with the South Africa drug maker.